Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135641 | 0.85 | MEN1 (0.33) | MEN1CYP1A2KMT2AALDH1A1THRB | |
| SCHEMBL10447893 | 0.85 | CYP2D6 (0.41) | MEN1CYP1A2KMT2AALDH1A1FFAR3 | |
| SCHEMBL3947952 | 0.79 | FFAR3 (0.32) | MEN1CYP1A2KMT2AALDH1A1FFAR3 | |
| SCHEMBL6155159 | 0.79 | CES2 (0.40) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6154156 | 0.79 | CES2 (0.40) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL31143106 | 0.79 | CA1 (0.30) | — | |
| SCHEMBL29963438 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL32680313 | 0.76 | TDP1 (0.32) | ALDH1A1FFAR3TSHR | |
| SCHEMBL2455289 | 0.76 | ALDH1A1 (0.36) | MEN1CYP1A2KMT2AALDH1A1FFAR3 | |
| SCHEMBL27746607 | 0.76 | ALOX15 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| EP-1560832-B1 | PYRIMIDO 4,5-D PYRIMIDINE DERIVATIVES WITH ANTICANCER ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7125887-B2 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040087552-A1 | Pyrrolidine modulators of ccr5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2004-05-06 | — | — | US | disclosed |
| EP-1326619-A2 | PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
| WO-2002034716-A2 | PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | MEN1 4707/4885CYP1A2 4059/4885KMT2A 4673/4885 |
| US-20040087552-A1 | Pyrrolidine modulators of ccr5 chemokine receptor activity | CCR5, CCR1, CXCR1 | MEN1 4711/4885CYP1A2 3957/4885KMT2A 4657/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | MEN1 4705/4885CYP1A2 601/4885KMT2A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.